Evidence map›Paper›PMID 38733291›Full record

ArticleAdvanced healthcare materials2024

Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS-CoV-2 Through Mutant Bacteriophage Qβ-Receptor Binding Domain Conjugate.

Zibin Tan, Canchai Yang, Po-Han Lin, Sherif Ramadan, Weizhun Yang, Zahra Rashidi, Shuyao Lang, Fatemeh Shafieichaharberoud, Jia Gao, Xingling Pan and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zibin TanDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Canchai YangDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, 48824, USA.
Po-Han LinDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Sherif RamadanDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Weizhun YangDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Zahra RashidiDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Shuyao LangDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Fatemeh ShafieichaharberoudDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Jia GaoDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Xingling PanDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.
Nachy SoloffHatzalah of Michigan, 13650 Oak Park Blvd., Oak Park, MI, 48237, USA.
Xuanjun WuNational Glycoengineering Research Center, Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao, Shandong, 250100, China.
Steven BolinVeterinary Diagnostic Laboratory, Michigan State University, East Lansing, MI, 48824, USA.
Dohun PyeonDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, 48824, USA.
Xuefei HuangDepartment of Chemistry, Michigan State University, East Lansing, MI, 48824, USA.ORCID 0000-0002-6468-5526

Funding

Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccinesR01AI146210 · NIAID · MICHIGAN STATE UNIVERSITY · PI HUANG, XUEFEI · 2019 to 2023
$1.5M
Michigan State UniversityNIAID NIH HHS R01 AI146210NIH HHS R01AI146210
6 · The paper itself

Abstract

More than 3 years into the global pandemic, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a significant threat to public health. Immunities acquired from infection or current vaccines fail to provide long term protection against subsequent infections, mainly due to their fast-waning nature and the emergence of variants of concerns (VOCs) such as Omicron. To overcome these limitations, SARS-CoV-2 Spike protein receptor binding domain (RBD)-based epitopes are investigated as conjugates with a powerful carrier, the mutant bacteriophage Qβ (mQβ). The epitope design is critical to eliciting potent antibody responses with the full length RBD being superior to peptide and glycopeptide antigens. The full length RBD conjugated with mQβ activates both humoral and cellular immune systems in vivo, inducing broad spectrum, persistent, and comprehensive immune responses effective against multiple VOCs including Delta and Omicron variants, rendering it a promising vaccine candidate.

Indexed as

B-LymphocytesCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesAllolevivirusAnimalsAntibodies, ViralCOVID-19 VaccinesFemaleHumansImmunity, CellularMiceMice, Inbred BALB CMutationProtein DomainsAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2mutant QβSARS‐CoV‐2vaccinevirus‐like particle

Identifiers

PMID38733291
PMCPMC11305917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.